Category: clinical study retractions

Authors retract HER-2 endometrial cancer paper for 2x publication

OGSFile this one under strange excuses.

A cancer paper was retracted on September 17 for a double publication. According to the notice in which the authors admit to duplicating the “opening to the readers,” which we assume is the introduction, there was no need to cite the article “because it had not yet been printed at that time.”

Here’s the notice for “The effect of HER-2 polymorphism according to age on the risk and pathologic feature of endometrial cancer”: Continue reading Authors retract HER-2 endometrial cancer paper for 2x publication

Asthma study yanked for serious ethical violations

springerplusA paper in SpringerPlus on treating asthma with antioxidants was retracted on September 25 for something of a trifecta of ethical problems.

The retraction notice indicates that the patients never consented, there was no ethical review, and the university supposedly overseeing the study had no knowledge of it:

Continue reading Asthma study yanked for serious ethical violations

Cell line switch sinks PLoS ONE cancer paper

plosWe’ve written before about how common cell line mix ups are in cancer research; according to a 2012 Wall Street Journal article (paywalled), between a fifth and a third of cancer cell lines tested by suspicious researchers turned out to be misidentified.

Obviously, mistakenly studying the wrong kind of cancer is a waste of precious resources, both time and money. And it’s clear the problem hasn’t gone away. PLoS ONE just retracted a cancer paper originally published in December 2012 for studying two cell lines that had been contaminated by other cell types.

Here’s the notice for “Epithelial Mesenchymal Transition Is Required for Acquisition of Anoikis Resistance and Metastatic Potential in Adenoid Cystic Carcinoma”:
Continue reading Cell line switch sinks PLoS ONE cancer paper

Yet another study of widely touted cancer “cure” retracted

cancer immunology immunotherapyA third study of GcMAF, a protein being used to treat a variety of conditions from AIDS to autism to cancer, all without the blessing of health agencies, has been retracted.

Here’s the notice in Cancer Immunology, Immunotherapy for “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF:” Continue reading Yet another study of widely touted cancer “cure” retracted

Journal makes it official, retracting controversial autism-vaccine paper

translational neurodegenerationA little more than a month after removing a highly criticized article that claimed the measles-mumps-rubella (MMR) vaccine increased the risk of autism in African American boys, Translational Neurodegeneration has officially retracted the paper.

Here’s the notice, dated yesterday: Continue reading Journal makes it official, retracting controversial autism-vaccine paper

Critics of Poldermans’ work baffled by NEJM stance on DECREASE papers

EBPOM_00219_M3
Don Poldermans

A pair of researchers who have been calling for the retraction of two papers by cardiology researcher Don Poldermans say the New England Journal of Medicine is  “not justified” “disappointing” in its refusal to pull the articles.

A little background: Poldermans resigned from Erasmus University in 2011 after having been accused of misconduct. Last week, we reported that the European Heart Journal had issued an expression of concern for a 2001 article on which he was first author.

The New England Journal of Medicine added editor’s notes to two of Poldermans’ articles. But as Larry Husten at Forbes reports, the journal has no intention of retracting the papers: Continue reading Critics of Poldermans’ work baffled by NEJM stance on DECREASE papers

Publisher issues statement of concern about HIV denial paper, launches investigation

frontiers phThe publisher Frontiers has issued a Statement of Concern about a paper denying that HIV causes AIDS, and has launched an investigation into how the paper was published in the first place.

The paper, “Questioning the HIV-AIDS hypothesis: 30 years of dissent,” is written by Patricia Goodson of Texas A&M University and was published on September 23 in Frontiers in Public Health. As Tara Smith, who blogged about the paper yesterday, notes: Continue reading Publisher issues statement of concern about HIV denial paper, launches investigation

Notice fails to get to the heart of cardiology retraction

cmjThis one is a little odd.

A cardiology paper from China has been retracted because “permission to report these discussions was not sought nor obtained,” though it’s unclear what “the discussions” refers to. The person to whom the discussions are attributed to in the retraction, Ji Bingyang, is not an author on the paper, and none of his papers are cited in the retracted article.

Here’s the notice in the Chinese Medical Journal for “A novel rat model of cardiopulmonary bypass for deep hypothermic circulatory arrest without blood priming”:
Continue reading Notice fails to get to the heart of cardiology retraction

Data questions prompt retraction of PLOS ONE cardiovascular paper

plosonePLoS One has retracted a 2013 article on atherosclerosis in mice over concerns about the integrity of the data.

The paper, “The Effect of Soluble RAGE on Inhibition of Angiotensin II-Mediated Atherosclerosis in Apolipoprotein E Deficient Mice,” came from a group of researchers in South Korea.

It purported to show that: Continue reading Data questions prompt retraction of PLOS ONE cardiovascular paper

“Wide differences in the memories” prompt expression of concern for Poldermans paper

EHJThe European Heart Journal has issued an expression of concern for a 2014 2001 paper by Don Poldermans, the Dutch heart researcher who stepped down from his post at Erasmus University after being accused of misconduct.

The article, “Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery,” appeared in July and reported data from the DECREASE trial. Poldermans, who left Erasmus in 2011, has acknowledged failing to receive informed consent from some patients in one phase of the DECREASE study but denied having fabricated results.

According to the notice: Continue reading “Wide differences in the memories” prompt expression of concern for Poldermans paper